EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study

Alice Sandberg-Janzon, Pontus Karling

Neurogastroenterology & Motility · 2025

DOI: 10.1111/nmo.70063 ↗

At a glance

Beobachtungsstudie in Neurogastroenterology & Motility, 2025. Written by Alice Sandberg-Janzon and 1 co-authors. Institution: Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Major MEDLINE topics: Irritable Bowel Syndrome, Gastrointestinal Agents. Cited 2 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Region Västerbotten.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

There is limited data on how drugs prescribed for functional bowel disorders are re‐prescribed in clinical practice. This study aimed to investigate drug survival rates of different irritable bowel syndrome (IBS) treatments among patients referred to a gastroenterologist.

Methods

A retrospective observational study was conducted by reviewing medical charts of patients aged 18–50 years, diagnosed with IBS or an unspecified functional intestinal disorder between 2010 and 2018. Drug survival rates for various treatment categories were analyzed using Kaplan–Meier curves and log‐rank tests.

Results

A total of 1528 treatment attempts were recorded in 529 patients, with 883 classified as treatment‐naïve. Simethicones demonstrated significantly higher drug survival compared to bulking agents ( p = 0.009). Tricyclic antidepressants (TCA), loperamide, and simethicones all showed superior survival rates compared to osmotic laxatives ( p = 0.039, p = 0.025 and p = 0.003, respectively). Additionally, loperamide and simethicones had better survival rates than antispasmodics ( p = 0.046 and p = 0.012, respectively). At 60 months, the cumulative drug survival rate was highest for TCA (11%), followed by loperamide (10%) and simethicones (7%), all significantly outperforming bulking agents (1%) ( p = 0.002 for TCA vs. bulking agents, p = 0.002 for loperamide vs. bulking agents, and p = 0.006 for simethicones vs. bulking agents). For all treatment‐naïve attempts, the cumulative drug survival at 60 months was 6%.

Conclusions

The overall 60‐month drug survival for treatments prescribed in IBS is relatively low, suggesting that the effectiveness of current therapies remains limited. Among the medications studied, simethicone and TCAs demonstrated the best drug survival rates.

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeGastrointestinal AgentsHumansRetrospective StudiesAdultMaleFemaleMiddle AgedLoperamideYoung AdultAntidepressive Agents, TricyclicAdolescentSimethiconeLaxativesParasympatholytics

Author keywords

amitryptilinebulking agentsdrug survivalirritable bowel syndromeloperamidesiliconestricyclic antidepressants

Substances

LoperamideAntidepressive Agents, TricyclicGastrointestinal AgentsSimethiconeLaxativesParasympatholytics

Authors and institutions

  • Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Funding

  • Region Västerbotten

Cite

APA

Sandberg-Janzon, A., & Karling, P. (2025). Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70063

Vancouver

Sandberg-Janzon A, Karling P. Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study. Neurogastroenterology & Motility. 2025. doi:10.1111/nmo.70063

BibTeX
@article{SandbergJanzon2025,
  author = {Sandberg-Janzon, Alice and Karling, Pontus},
  title = {Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study},
  journal = {Neurogastroenterology & Motility},
  year = {2025},
  doi = {10.1111/nmo.70063}
}
Start for free →